Biblio Discovery — Demo Discovery Service

4 results for "Nicolas Mach"

Showing 1–4 · 0.82 seconds · RSS

  1. Journal Article Full text

    Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

    Giuseppe Curigliano; Hans A. J. Gelderblom; Nicolas Mach et al.

    Clinical Cancer Research · 2021 · English · OpenAlex Scopus

    Abstract Purpose: Sabatolimab (MBG453) and spartalizumab are mAbs that bind T-cell immunoglobulin domain and mucin domain-3 (TIM-3) and programmed death-1 (PD-1), respectively. This phase I/II study evaluated the safety and efficacy of sabatolimab, with or without spartalizumab, in patients with…

  2. Journal Article Full text

    SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial

    Sacha I. Rothschild; Alfred Zippelius; Eric Innocents Eboulet et al.

    Journal of Clinical Oncology · 2021 · English · OpenAlex Scopus

    PURPOSE: For patients with resectable stage IIIA(N2) non-small-cell lung cancer, neoadjuvant chemotherapy with cisplatin and docetaxel followed by surgery resulted in a 1-year event-free survival (EFS) rate of 48% in the SAKK 16/00 trial and is an accepted standard of care. We investigated the…

  3. Journal Article

    Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer

    Ravindra Uppaluri; Robert I. Haddad; Yungan Tao et al.

    New England Journal of Medicine · 2025 · English · OpenAlex Scopus

    BACKGROUND: The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell carcinoma (HNSCC) is unclear. METHODS: In this phase 3, open-label trial, we randomly assigned participants with…